Latest News Feed
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates
Total net revenue of $12.4 million
Adjusted EBITDA1 of $(2.8) million, which includes EXXUA™ (gepirone) extended-release tablets ("EXXUA") launch investments as the Company enters the over $22 billion United States prescription major depressive disorder ("MDD") market
$26.7 million cash balance at March 31, 2026
Company to host conference call and webcast today, May 13, 2026, at 4:30 p.m. Eastern time
Total net revenue of $15.2 million
Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments
$30.0 million cash balance at December 31, 2025
Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market
Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIs
Now commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to support patient access
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availability
EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain compared to placebo
Total net revenue of $13.9 million
Net income of $2.0 million, or $0.21 net income per share basic
Adjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments
$32.6 million cash balance at September 30, 2025
Company remains on track to launch EXXUA™ (gepirone) extended-release tablets ("EXXUA") in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market
Company to host conference call and webcast today, November 13, 2025, at 4:30 p.m. Eastern time
Full year fiscal 2025 net revenue of $66.4 million
Full year fiscal 2025 net loss of $13.6 million
Full year fiscal 2025 adjusted EBITDA1 of $9.2 million
$31.0 million cash balance at June 30, 2025
Exclusive agreement in June 2025 to commercialize EXXUA™ (gepirone) extended-release tablets ("EXXUA") is expected to serve as a major growth catalyst; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market with what the Company believes to be a novel first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD
Company to host conference call and webcast today, September 23, 2025, at 4:30 p.m. Eastern time
Term loan maturity extended by 12 months to June 2029
Principal balance on term loan expanded to $13.0 million from $11.1 million currently
Expanded revolving line of credit facility by $1.5 million
Expanded facilities allow for added working capital flexibility as commercial launch of EXXUA is anticipated to occur in the fourth calendar quarter of 2025
Gross proceeds from offering total $16.6 million.
Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders.
Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.
EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.
EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts.
Conference call to discuss the EXXUA opportunity and commercialization plan scheduled for Wednesday, June 11, 2025, at 4:30 p.m. Eastern time.
Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing.
Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.
EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.
EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts.
EXXUA transaction financed by long-term, healthcare-focused institutional investors, including Aytu's largest shareholder Nantahala Capital Management, Stonepine Capital Management, Aytu management, and new institutional shareholders.
Company to conduct 1x1 meetings on April 24, 2025
Net income of $0.8 million
Adjusted EBITDA1 of $1.3 million
Pediatric Portfolio net revenue up 86% sequentially
First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023
$20.4 million cash balance at December 31, 2024
Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time
Net income of $1.5 million
Adjusted EBITDA1 of $1.9 million
ADHD Portfolio net revenue up 1% to $15.3 million
Pediatric Portfolio net revenue up 54% sequentially
$20.1 million cash balance at September 30, 2024
Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flow
Ryan Selhorn promoted to Chief Financial Officer
Company to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time
Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada